Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure

被引:75
作者
Zoccali, C
Mallamaci, F
Tripepi, G
Cutrupi, S
Parlongo, S
Malatino, LS
Bonanno, G
Rapisarda, F
Fatuzzo, P
Seminara, G
Stancanelli, B
Nicocia, G
Buemi, M
机构
[1] CNR, Inst Biomed Clin Epidemiol & Pathophysiol Renal D, Reggio Di Calabria, Italy
[2] Univ Catania, Dept Internal Med, L Condorelli Inst, I-95124 Catania, Italy
[3] Univ Messina, Clin Pathol Unit, I-98100 Messina, Italy
[4] Univ Messina, Nephrol Chair, I-98100 Messina, Italy
关键词
C-reactive protein; cardiovascular risk; dialysis; fibrinogen; inflammation; uremia;
D O I
10.1046/j.1365-2796.2003.01180.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Fibrinogen is an established predictor of cardiovascular events in the general population but the relationship between fibrinogen, mortality and incident cardiovascular complications has been very little investigated in patients with end-stage renal disease (ESRD). Design and subjects. We investigated the relationship between fibrinogen and all cause mortality and cardiovascular outcomes in a prospective cohort study in 192 patients on chronic haemodialysis treatment (follow-up: 34 +/- 16 months). Results. Fibrinogen was significantly higher in patients who died during the follow-up than in those who survived. Similarly, fibrinogen was higher in patients who had fatal or nonfatal cardiovascular events than in event free patients. On multivariate Cox regression analysis fibrinogen was an independent predictor of survival [hazard ratio (1 g L-1 increase in plasma fibrinogen): 1.19, 95% confidence interval (CI): 1.05-1.35, P = 0.006] and a highly significant (P = 0.0008), independent predictor of fatal and nonfatal cardiovascular events [hazard ratio (1 g L-1 increase in plasma fibrinogen): 1.25, 95% CI: 1.10-1.43] in a model including traditional risk factors and serum C-reactive protein (CRP) and plasma homocysteine. Conclusions. Fibrinogen is as an independent risk factor for overall and cardiovascular mortality in patients with ESRD. Intervention studies are required to see whether reducing plasma fibrinogen may help to curb the exceedingly high cardiovascular risk of the uremic population.
引用
收藏
页码:132 / 139
页数:8
相关论文
共 40 条
[1]   Premature cardiovascular disease in chronic renal failure [J].
Baigent, C ;
Burbury, K ;
Wheeler, D .
LANCET, 2000, 356 (9224) :147-152
[2]   Malnutrition, cardiac disease, and mortality:: An integrated point of view [J].
Bergström, J ;
Lindholm, B .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :834-841
[3]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[4]   Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients [J].
Boaz, M ;
Matas, Z ;
Biro, A ;
Katzir, Z ;
Green, M ;
Fainaru, M ;
Smetana, S .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (03) :438-444
[5]   Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response [J].
Borawski, J ;
Naumnik, B ;
Pawlak, K ;
Mysliwiec, M .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (07) :1442-1447
[6]   Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study [J].
Bostom, AG ;
Shemin, D ;
Lapane, KL ;
Sutherland, P ;
Nadeau, MR ;
Wilson, PWF ;
Yoburn, D ;
Bausserman, L ;
Tofler, G ;
Jacques, PF ;
Selhub, J ;
Rosenberg, IH .
ATHEROSCLEROSIS, 1996, 125 (01) :91-101
[7]   Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease - Meta-analyses of prospective studies [J].
Danesh, J ;
Collins, R ;
Appleby, P ;
Peto, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (18) :1477-1482
[8]   On the epidemic of cardiovascular disease in patients with chronic renal disease and progressive renal failure: A first step to improve the outcomes [J].
Eknoyan, G .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :S1-S4
[9]   FIBRINOGEN AS A CARDIOVASCULAR RISK FACTOR - A METAANALYSIS AND REVIEW OF THE LITERATURE [J].
ERNST, E ;
RESCH, KL .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (12) :956-963
[10]   The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease [J].
Foley, RN ;
Parfrey, PS ;
Harnett, JD ;
Kent, GM ;
Murray, DC ;
Barre, PE .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (01) :53-61